• All facets of drug design, including rational approaches
• Establishment of structure-activity-relationship (SAR) and structure-property-relationship (SPR)
• Multi-parameter optimization (hit-to-lead and lead-to-candidate), identification of drug-like molecules
• Computational chemistry, cheminformatics, virtual screening
• (Parallel) Organic synthesis
• Natural products
• Peptides

• Development of biochemical, phenotypic and cellular assays for new targets and phenotypes
• Adaption of existing assays for MTS and HTS (up to 1536-well format)
• Execution of biochemical and cellular primary screening campaigns on two fully automated robotic systems
• High content screening
• Biophysical methods (surface plasmon resonance, microscale thermophoresis, thermal shift assays)
• State-of-the-art compound logistics including automated sample storage and quality control
• Centralized data warehouse for registration of compounds, data processing, storage of biological data and data visualization
• Access to diverse compound collections (internal library and partner libraries)¹
• Support for optimization cycles in medicinal chemistry

¹Use of partnered screening facilities and various diverse libraries, e.g., access to professional and proprietary industrial compound libraries holding approx. one million substances.

• Cellular pharmacology
• Evaluation of efficacy and toxicity
• Studies of mode of action, functions and phenotypes of compounds
• Cellular selectivity
• Identification of biomarkers and target deconvolution
• Identification and verification of pharmacodynamic markers

• Assessment of physicochemical and biopharmaceutical properties, safety and efficacy of drug candidates
• In vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) and DMPK (drug metabolism and pharmacokinetics) profiling
• In vivo PK/PD studies²
• Metabolite studies²
• LC-MS-based bioanalytical investigation
• Coordination of in vivo efficacy studies²
• Early toxicity studies, tolerability, genotox, MTD, etc.²

²in vivo studies only carried out in cooperation with our academic partners or with reliable service providers

• Network of versatile antibody generation platforms (hybridoma and phage display)
• De-risking the antibody development path with respect to productivity, scalability, stability, etc.
• Antibody engineering and humanization
• Assay development and antibody lead selection according to industrial standards

• Aligning all players throughout the projects
• Goal-oriented project management according to industry standards
• Generating compound profiling cascades
• Implementing go/no-go decision points
• Transparent reporting to project investors and partners
• Coordinating activities of interdisciplinary teams of researchers
• Monitoring and supporting resource allocation

• Design and implementation of deal structures that meet the needs of all partners
• Strategic collaborations with pharma/investors
• Strong pharma/biotech/VC network
• Expertise in licensing IP and know-how to partners
• Support with spin-offs
• Track record in closing deals

• Coordination of patent filings and patent management with inventors, project partners and patent attorneys
• Coordination of due diligences
• Management of LDC’s IP portfolio